SRM-IV诊疗系统在上半规管良性阵发性位置性眩晕诊治中的应用价值  

Application Value of Srm-iv System in Diagnosis and Treatment of Superior Semicircular Canal Benign Paroxysmal Positional Vertigo

作　　者：杨秋云 蒙楠 韦福依[1] YANG Qiuyun;MENG Nan;WEI Fuyi(Guangxi Baise People's Hospital,Guangxi Baise 533000,China)

机构地区：[1]广西壮族自治区百色市人民医院耳鼻喉科,广西百色533000

出　　处：《河北医学》2021年第7期1178-1182,共5页Hebei Medicine

基　　金：广西省卫健委科研课题,(编号:Z20201146)

摘　　要：目的:观察SRM-IV诊疗系统在上半规管良性阵发性位置性眩晕(AC-BPPV)诊治中的应用价值。方法:前瞻性选取2018年2月至2021年2月期间百色市人民医院收治的110例AC-BPPV患者为研究对象,采用简单随机抽样法随机分为试验组(n=55例)与对照组(n=55例)。试验组对患者采用SRM-IV诊疗系统治疗,对照组给予患者常规手法复位治疗,两组均治疗1周。比较两组患者治疗1周后的治疗总有效率、治愈时间、主客观症状以及生活质量改善情况、并发症发生情况及复发率。结果:试验组的治疗总有效率(96.36%)明显高于对照组(81.82%),差异有统计学意义(χ^(2)=11.652,P<0.05);试验组的治愈时间(6.13±0.66)d明显短于对照组(6.99±0.74)d,差异有统计学意义(t=5.443,P<0.05);试验组主客观症状相关评分(UCLA-DQ、MSQ)治疗前后差值(2.46±0.14)分、(63.10±6.59)分,明显高于对照组的(1.58±0.28)分、(49.22±5.41)分;生活质量(DHI)评分治疗前后差值(36.12±2.33)分,显著高于对照组的(22.50±2.10)分;试验组并发症发生率(3.64%)明显低于对照组的18.18%,差异有统计学意义(P<0.05);试验组患者的复发率(3.64%)与对照组(5.45%)相比,差异无统计学意义(P>0.05)。结论:SRM-IV诊疗系统在上半规管良性阵发性位置性眩晕诊治中发挥积极作用,治疗效果显著且并发症少,安全可靠,同时显著改善患者主客观症状与生活质量,适于临床实践与应用。Objective:To observe the application value of SRM-IV system in the induction test of benign paroxysmal positional vertigo of superior semicircular canal(AC-BPPV).Methods:110 patients with ac-bppv admitted to Baise people's Hospital from February 2018 to February 2021 were prospectively selected and randomly divided into experimental group(n=55)and control group(n=55)by simple random sampling method.The patients in the experimental group were treated with srm-iv diagnosis and treatment system,while the patients in the control group were treated with conventional manipulative reduction.Both groups were treated for 1 week.The total effective rate,cure time,subjective and objective symptoms,improvement of quality of life,occurrence of complications and recurrence rate of the two groups were compared after one week of treatment.Results:The total effective rate of the experimental group(96.36%)was significantly higher than that of the control group(81.82%),the difference was statistically significant(χ^(2)=11.652,P<0.05).The cure time of the experimental group[(6.131±66)D]was significantly shorter than that in the control group[(6.990±74)D],the difference was statistically significant(t=5.443,P<0.05).The difference of subjective and objective symptom related scores(UCLA-DQ,MSQ)before and after treatment in the experimental group[(2.460.05)]±14)](63.100±59),which was significantly higher than that of the control group[(1.586±28)(49.220±41)].The difference of quality of life(DHI)score before and after treatment[(36.121±33),which was significantly higher than that of the control group[(22.502±10)].The incidence of complications in the experimental group(3.64%)was significantly lower than that in the control group(18.18%),the difference was statistically significant(P<0.05).There was no significant difference in the recurrence rate between the experimental group(3.64%)and the control group(5.45%)(P>0.05).Conclusion:The SRM-IV diagnosis and treatment system plays an active role in the diagnosis and treatment of ben

关 键 词：上半规管良性阵发性位置性眩晕 SRM-IV诊疗系统 主客观症状 生活质量 并发症 

分 类 号：R764[医药卫生—耳鼻咽喉科]